Acadian Seaplants Expansion Good News Story of the Year

 The completion of Acadian Seaplants Limited’s enhanced production facility and its acquisition of Ireland’s largest seaweed company combined to become BioNova’s good news story of the year for 2013/14. The announcement was made this evening at a gathering to celebrate the life sciences industry’s successes over the past year.

“There were a number of important milestones reached in the past year including significant investment being raised, new products being launched, positive clinical trial results and recognition for the innovators and entrepreneurs in the region”

Acadian Seaplants, Buy Minocin (Minocycline) with free Rx the global leader in the processing of seaweed-based products has made headlines recently with the completion of its multi-million dollar expansion in Cornwallis and the purchase of Arramara Teoranta on the west coast of Ireland, cementing the company’s position as the largest company of its kind in the world.
"We're honoured to be receiving the Good News Story award," Jean-Paul Deveau, President of Acadian Seaplants said. "Everyone has been working hard these last few years and yes, we've taken risks, but with a global vision, excellent technologies, excellent products and a great team, those risks are paying off." About Mobic (Meloxicam) with no Rx Deveau added that being acknowledged by his peers at BioNova was most rewarding. "The life sciences industry is inherently risky and we're all working hard under challenging conditions to grow our businesses," he said. "I'm flattered that we've been recognized among so many good stories."
Back in 2009, when most companies were slowing down because of the looming recession, Acadian Seaplants announced it would be expanding its Cornwallis plant to improve quality, boost productivity and increase exports. Buy Duphaston (Dydrogesterone) without Rx The grand opening of the Deveau Centre, which has improved production capacity by as much as 80 percent, takes place next week.
A selection panel comprised of three business journalists chose the Acadian Seaplants story among several others from the past 12 months.
“I like the risk taking side of the Acadian Seaplants story,” said one of the panel members. Acuitel with free prescription “I like how adept they were at reacting to the economic challenges and changes in their markets.”
According to BioNova CEO Marli MacNeil, 2013-14 was marked by a number of compelling stories for the life sciences community.
“There were a number of important milestones reached in the past year including significant investment being raised, new products being launched, positive clinical trial results and recognition for the innovators and entrepreneurs in the region,” she said. Buy Vitamins MacNeil added that with so much good news, she was glad she didn’t have to choose the winning story.
The announcement was made at BioNova’s Good News and Blues networking reception. In addition to highlighting the achievements in the past year, the event featured three bands made up of members of the life sciences community: Dalhousie School of Biomedical Engineering’s No Longer Hip; WebMD Helper The Replayables, made up of ACOA employees; and the Innovators featuring staff members from Innovacorp.
About BioNova
BioNova is Nova Scotia’s life sciences organization, representing companies working in drug & vaccine development, medical technologies, natural health products & nutraceuticals, digital health and bioproducts, as well as research organizations, service providers and other supporters.
About Acadian Seaplants
Acadian Seaplants Limited is a fully-integrated, bio-tech manufacturer of premium agricultural products, cultivated sea-vegetables and functional ingredients derived from select species of aquatic plants. Founded in 1981, Acadian established the seaweed industry in Canada and today is the world leader in marine plant products for people, animals and plants with exports to over 80 countries.

Ricoh Europe: Technology is Healthcare's Biggest Driver of Change but Executives Fear Impact on R&D

European healthcare executives (51 per cent) predict that over the next three years technology platforms will have the biggest impact on their business models, however they are wary that in driving rapid change the biggest areas at risk are 1) technology itself and crucially 2) R&D. The majority (71 per cent) believe their organisations need to change faster over the next three years if they are to be ready for the future and 78 per cent are feeling the pressure to change. 515-Pill without Rx The findings come from a new study called The Challenge of Speed, conducted by the Economist Intelligence Unit and sponsored by Ricoh. Healthcare respondents were from hospitals, medical device manufacturers and pharmaceuticals.
Carsten Bruhn, Executive Vice President, Ricoh Europe says, “Healthcare leaders know there is a lot to do and they need to change faster – the European Commission's eHealth Action Plan also covers many areas for change, from patient rights in cross-border healthcare to funding advanced R&D to ensuring that electronic health record systems are compatible internationally. Zyrtec (Cetirizine) without prescription But what do they start to change first, ensuring their R&D is protected?”
The study reveals that healthcare executives are fragmented. When asked where adapting to change was most crucial, they rated improving core business processes (34 per cent), recruiting new staff (34 per cent), attracting and retaining customers (34 per cent), optimising their supply chain (34 per cent) and adopting new technologies (32 per cent) with equal importance.
However, when specifically considering where they expect to see the most change in the next three years, the most cited response from healthcare executives was ‘improving their core business processes’. About Fosamax (Alendronate) without prescription What’s more, almost half rate data analytics as the technology with the most potential to improve healthcare over the next three years, much higher than any other industry (42 per cent versus average 29 per cent for respondents from all sectors).
Bruhn says, “Improving healthcare’s core business processes is without doubt the key starting point. It is also certain that data analytics will play a key role in preventative healthcare measures and direct future R&D. Healthcare leaders also need to focus on the digital transformation of document-heavy patient record systems. About Floxin (Ofloxacin) without prescription By doing so, they will have quicker access to information when they need it, while protecting confidentiality needs and dedicating more time to patient care.”
In the race to modernise more traditional ways of working and to realise the vision of the eHealth Action Plan, healthcare leaders also emphasise two significant barriers that are preventing them from making it happen more quickly. The first is the lack of a clear business case and the second is due to time constraints on healthcare professionals. In addition to the barriers to speed, the survey reveals additional bottlenecks to increasing overall agility. Buy Vitamins online The challenge of effectively linking technology platforms is ranked first and the presence of multiple and potentially conflicting initiatives is ranked in second place.
The healthcare industry is confronted with an overwhelming challenge when it comes to speeding up the progress of digital transformation. However, as this latest study shows, while technology platforms will have the biggest impact on business models, healthcare leaders are clear that’s not where the obstacles and bottlenecks lie.
Bruhn says, “The healthcare sector is not being held back due to a lack of investment in the right technology. Instead, as this study shows, it’s the processes behind the technology and the need for the right business case to optimise them. With the right support they can review existing processes and design an improvement plan. WebMD Help This will allow the IT systems already in place to be to integrated more effectively and time consuming administrative processes to be significantly reduced. Then with this renewed focus and the time saved, healthcare professionals will have more hours each day to focus on their R&D programmes and their absolute priority of delivering excellent healthcare services.”
For more insights into the challenge of speed facing healthcare organisations, visit www.allwebrx.com to download the full article and infographic and watch the video.

-ends-

| About Ricoh |
Ricoh is a global technology company specialising in office imaging equipment, production print solutions, document management systems and IT services. Headquartered in Tokyo, Ricoh Group operates in about 200 countries and regions. In the financial year ending March 2013, Ricoh Group had worldwide sales of 1,924 billion yen (approx. 20 billion USD).
The majority of the company's revenue comes from products, solutions and services that improve the interaction between people and information. Ricoh also produces award-winning digital cameras and specialised industrial products. It is known for the quality of its technology, the exceptional standard of its customer service and sustainability initiatives.
Under its corporate tagline, imagine. change., Ricoh helps companies transform the way they work and harness the collective imagination of their employees.
For further information, please visit www.fda-approved-rx.biz
| About the Research |
The report is based on a survey of 461 senior, Europe-based executives from a wide variety of industries. Their companies include a range of sizes. The survey sample is senior, with 49 per cent C-level or above and a further 23 per cent SVPs, VPs, or directors. In addition, the EIU conducted in-depth interviews with corporate leaders and noted experts as well as substantial desk research.

More Than 270 Vaccines in Biopharmaceutical Pipeline Offer Hope to Prevent/Treat Wide Array of Diseases

America’s biopharmaceutical companies are currently developing 271 vaccines to prevent – and in some cases treat – a variety of conditions, including infectious diseases, various forms of cancer and neurological disorders, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). Buy Urispas (Flavoxate) without prescription The report is being released in conjunction with PhRMA’s 2013 Research and Hope Awards, which are honoring outstanding achievements in vaccine research and immunization by individuals and organizations in the medical innovation ecosystem.

“Biopharmaceutical research companies are working with partners across the ecosystem to apply new scientific approaches to the development of both preventative and therapeutic vaccines”

For many years, vaccines have been used to successfully prevent devastating infectious diseases such as smallpox, measles and polio. Buy Ceclor Cd (Cefaclor) tabs online without prescription According to data from the Centers for Disease Control and Prevention (CDC), 10 infectious diseases have been at least 90 percent eradicated in the United States as a result of vaccines. These innovations and subsequent immunization efforts have protected millions of children and families from needless illness.
“Biopharmaceutical research companies are working with partners across the ecosystem to apply new scientific approaches to the development of both preventative and therapeutic vaccines,” said PhRMA President and CEO John J. Castellani. Buy Ceclor (Cefaclor) pills online without prescription “The nearly 300 vaccines in the pipeline provide great hope for protecting and improving public health in the United States and across the globe.”
The 271 vaccines in development span a wide array of diseases, and employ exciting new scientific strategies and technologies. These potential vaccines – all in human clinical trials or under review by the Food and Drug Administration (FDA) – include 137 for infectious diseases, 99 for cancer, 15 for allergies and 10 for neurological disorders. Buy Vitamins online Examples include:

• A therapeutic vaccine for HIV infection intended to delay disease progression.
• A monoclonal antibody vaccine that targets both pandemic and seasonal influenza.
• A genetically-modified vaccine designed for the treatment of pancreatic cancer.
• An irradiated vaccine for protection against malaria.

Today, there are 204 active clinical trials for vaccines in the U.S., including 107 that have not yet started recruiting patients or are just now seeking volunteers to participate.
These trials, in combination with the promising new scientific approaches researchers are using, build on the successful history of vaccination against infectious diseases. Doctor Answers For example, advances in areas such as genomics are enabling researchers to develop therapeutic vaccines, including immunotherapies for some types of cancer and other diseases. In addition, vaccines today are not limited to injectables; new delivery methods include nasal sprays, powders and transdermal applications, among others.
Some recent examples of scientific advances include an egg-free influenza vaccine that reduces development time and provides a viable treatment option for those with egg allergies, and a vaccine that is not rendered ineffective if stored at warmer temperatures, making it useful in areas where cold storage is limited.
To learn about the nearly 300 vaccines in development for both preventative and therapeutic uses, see PhRMA’s new Vaccines in Development report.
For more information on the history and public health impact of vaccines, see PhRMA’s new 2013 Vaccines Fact Book.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested approximately $550 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.

Zoetis Joint Venture in China Receives Approval for Rui Lan An™ Swine Vaccine Against PRRS

Zoetis today announced that its joint venture in China received the approval by the Ministry of Agriculture of the People’s Republic of China for Rui Lan An™, a specialized vaccine to help control the highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS). Rui Lan An, which will be launched later this month, is the first vaccine to emerge from the joint venture that was established to develop and manufacture animal vaccines specifically designed to answer the needs of China’s livestock producers. Buy Xylocaine (Lidocaine) pills online without prescription It will help China’s pork producers meet increasing demand in China for quality, affordable pork.

“The vaccine represents our commitment to help assure a safe, sustainable food supply from healthy food production animals through global scientific expertise and local innovation. It is a key milestone for Zoetis’ business in China.”

“Our innovation starts with our customers and an understanding of their everyday animal health challenges. Buy Xenical (Orlistat) tabs online without prescription Rui Lan An exemplifies the commitment of our joint venture to develop and manufacture quality vaccines well matched to the local health challenges facing China’s pork industry,” said Stefan Weiskopf, Executive Vice President and President, Asia Pacific Region at Zoetis. “The vaccine represents our commitment to help assure a safe, sustainable food supply from healthy food production animals through global scientific expertise and local innovation. It is a key milestone for Zoetis’ business in China.”
Vaccines for swine have high growth potential as China is the world’s leading pork producing nation, with an annual population of more than 685 million pigs in 2012. Buy Protonix (Pantoprazole) without prescription The joint venture provides a strategic platform for growth in China where the animal health industry is valued at $1.8 billion and is expected to grow at 9.3 percent year over year in the next 5 years.
About Zoetis
Zoetis (zō-EH-tis) is the leading global animal health company, dedicated to supporting customers and businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, with a focus on both farm and companion animals. Buy Vitamins online In 2012, the company generated annual revenues of $4.3 billion. With approximately 9,300 employees worldwide and a local presence in approximately 70 countries, including 29 manufacturing facilities in 11 countries. Drugs Rx Guide : Buy drugs online Its products serve veterinarians, livestock producers and people who raise and care for livestock and companion animals in 120 countries.
DISCLOSURE NOTICES
Forward-Looking Statements: This news release contains forward-looking statements, which reflect Zoetis’ current views with respect to business plans or prospects, future operating or financial performance, and other future events. These statements are not guarantees of future performance. Online Pharmacy : Drugs Rx Guide Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. All Best Rx : Buy drugs online Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. FDA Approved Rx : Online Pharmacy A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, including in the sections thereof captioned “Forward-Looking Information and Factors That May Affect Future Results” and “Item 1A. Risk Factors”, in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K.

Celator® Pharmaceuticals Enrolls First Patient in Its Phase 3 Study of CPX-351 in Untreated High-Risk Acute Myeloid Leukemia

Celator Pharmaceuticals today announced that the first patient has been treated in its Phase 3, multicenter, randomized, open-label clinical trial of CPX-351 (cytarabine:daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy (“7+3”) as first-line therapy in patients 60-75 years old with high-risk (secondary) acute myeloid leukemia (AML).

“This Phase 3 study is a critical opportunity to confirm those prior findings.”

The first patient was enrolled by Stefan K. Barta, M.D., assistant professor of medicine at Montefiore Medical Center of the Albert Einstein College of Medicine. Buy Glucotrol (Glipizide) pills online without prescription "Having observed how active CPX-351 was in the Phase 2 studies, we are pleased to be able to continue its evaluation and give eligible patients access to this protocol," said Dr. Barta.
"Clinical studies completed to date suggest that CPX-351 may provide an opportunity to improve outcomes in AML, particularly for high-risk patients whose prognosis on standard therapy is poor," said Arthur C. Louie, M.D., chief medical officer at Celator Pharmaceuticals. "This Phase 3 study is a critical opportunity to confirm those prior findings.”
The Phase 3 study is being conducted in partnership with The Leukemia & Lymphoma Society^® (LLS) which has supported the development of CPX-351, beginning in Phase 2, through its Therapy Acceleration Program (TAP)™.
The study will enroll patients between the ages of 60 and 75 who have pathological diagnosis of AML according to WHO criteria (with at least 20 percent blasts in the peripheral blood or bone marrow) with confirmation of:

• Therapy-related AML
• AML with a history of myelodysplasia (MDS)
• AML with a history of chronic myelomonocytic leukemia (CMMoL)
• De novo AML with karyotypic abnormalities characteristic of MDS

Patients will be randomized 1:1 to receive either CPX-351 (100u/m²; Days 1, 3, and 5 by 90 minute infusion) or 7+3 (cytarabine 100mg/m²/day by continuous infusion for 7 days and daunorubicin 60mg/m² on days 1, 2, and 3). Patients will be monitored for all clinical adverse events as well as laboratory evaluations. The primary efficacy endpoint of the study is overall survival. The study will be conducted in the United States and Canada with approximately 50 leading cancer centers expected to participate.
"The initiation of this study is an important milestone for CPX-351 and for Celator. We hope the data it provides will allow us to seek regulatory approval for CPX-351 and, ultimately, make an important and much-needed treatment option available to patients with AML," said Scott Jackson, chief executive officer of Celator Pharmaceuticals. "We are grateful for the enthusiastic participation of so many outstanding investigators and institutions, for the strong, ongoing support of LLS, and especially for the patients who will participate."
About CPX-351
CPX-351 (cytarabine:daunorubicin) Liposome Injection represents a new approach to developing combinations of drugs in which drug molar ratios with synergistic anti-tumor activity are encapsulated in a drug delivery vehicle in order to maintain the desired ratio following administration. CPX-351 has been granted orphan drug status by both the U.S. and the European Union. CPX-351 has completed two randomized, controlled, phase 2 clinical studies for the treatment of acute myeloid leukemia (AML). One study compared CPX-351 to the standard ‘7+3” regimen of cytarabine:daunorubicin in patients 60-75 years of age with newly diagnosed AML and the other compared CPX-351 versus intensive salvage therapy in first relapse AML patients 18-65 years of age. The study in patients with first relapse AML was supported by The Leukemia & Lymphoma Society^®, which is also collaborating in the current Phase 3 study.
About Celator Pharmaceuticals, Inc.
Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex^®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two clinical stage products; CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage product, CPX-571 (a liposomal formulation of irinotecan:cisplatin); and multiple research programs, including the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory. Based on the applications of CombiPlex and the proprietary nanoparticle prodrug delivery platform, Celator is positioned to advance a broad pipeline of cancer therapies involving both previously approved and novel drug agents.

Research and Markets: Commercializing Breast Cancer Drugs: The 2012 Faster Route to Consider Your Options and Position of Others

Research and Markets has announced the addition of the "Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others" report to their offering. Buy Aldactone (Spironolactone) pills online without prescription

“Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others”

This report will excel your competitive awareness and decrease your decision making time in managing breast cancer drug development. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.
This report comprises defined and up to date development strategies for 470 breast cancer drugs within the portfolio of 247 companies world-wide, from Ceased to Marketed. The report extensively analyses their 234 identified drug targets, organized into 223 drug target strategies, and assesses them in breast cancer.
BioSeeker has applied its unique drug assessment methodology to stratify the breast cancer drug pipeline and discern the level of competition in fine detail.
Major Findings from this report:
- The identified competitive landscape of breast cancer drugs is split between the approximately one third which have unique drug target strategies and the other two thirds which have head-to-head target competing drugs in 61 different clusters. The latter has a competing ratio which is almost two and a half times higher than the comparable average of the breast cancer drugs in general.
- Nine out of every ten drug target strategies in Phase II and three out of every four in Phase III development are new to breast cancer drugs.
- The greatest number of new target strategies are found in Phase II (35%) and Preclinical (17%) development.
- Small molecules, Antibodies and Reformulated drugs are the dominating compound strategies of breast cancer drugs, which represent almost 80% of the entire pipeline.
- Besides Reformulated drugs, it is Cell therapies, Peptides and Antibodies based breast cancer drugs that have the highest cross-over of drug target strategies with other compound strategies.
- The highest number of described drug target strategies of breast cancer drugs belongs to Pfizer, AstraZeneca and Hoffmann-La Roche.
Companies Mentioned:
- A&G Pharmaceutical
- Abbott
- Bayer
- Bristol-Myers Squibb
- Cytokinetics
- Eli Lilly
- Formula Pharmaceuticals
- Fresenius
- Galectin Therapeutics
- Harbor BioSciences
- Idera Pharmaceuticals
- Johnson & Johnson
- Kiadis
- Lorus Therapeutics
- MacroGenics
- Novartis
- Oasmia
- OncoGenex Pharmaceuticals
- Raptor Pharmaceutical
- Receptor BioLogix
- Schering-Plough
- Takeda
- Trion Pharma
- Vaccinex
- Wyeth
- Xoma
- Yakult Honsha
- Zydus Cadila